Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aetna Sees 80% Decrease In Rx Non-Sedating Antihistamine Use Post-Claritin

Executive Summary

Aetna's aggressive formulary management steps following the OTC switch of Claritin have led to an 80% decrease in use of prescription non-sedating antihistamines by members, the insurer says
Advertisement

Related Content

Antihistamine OTC Switch: WellPoint Will Not Sue If FDA Refuses Petition
Antihistamine OTC Switch: WellPoint Will Not Sue If FDA Refuses Petition
Allegra Hurt By Stocking, Late Allergy Season, Not Other Products – Aventis
Merck Singulair Presents Managed Care Test: Covering Asthma, Not Allergies
Schering OTC Claritin Will Launch In December Without Rx Transition Period
Schering OTC Claritin Will Launch In December Without Rx Transition Period
Advertisement
UsernamePublicRestriction

Register

PS042024

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel